374Water Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by 374Water Inc. (SCWO) on February 9, 2026, covering events occurring between February 4, 2026, and February 8, 2026. The filing addresses governance changes, including the resignation of a director, the appointment of a new director, and an amendment to a material agreement regarding board composition.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The only financial figure disclosed relates to a potential future financing transaction expected to exceed $120,000, though no guarantee of consummation is provided.
Material Changes and Governance Events
- Director Resignation: James Vanderhider resigned from the Board of Directors effective February 4, 2026. The resignation was not due to any disagreement with the Company.
- Nasdaq Non-Compliance: Mr. Vanderhider's departure created a vacancy on the Audit Committee, leaving it with only two members. This violates Nasdaq Listing Rule 5605(c)(2)(A), which requires three members. The Company notified Nasdaq on February 9, 2026, and intends to utilize the 180-day cure period to appoint a third qualified member.
- Director Appointment: Stephen McKnight was appointed to the Board on February 8, 2026, effective February 9, 2026, to fill the vacancy. Mr. McKnight is a principal of Pitt Southwest Investors and holds an MBA from the University of Pittsburgh.
- Material Agreement Amendment: On February 7, 2026, the Company entered into Amendment No. 1 to a Letter Agreement with Mr. Yaacov (Kobe) Nagar. The amendment stipulates that one year after the appointment of the third candidate to the Board, the Company and Mr. Nagar will mutually identify a replacement candidate for that third seat.
Outlook, Risks, and Contingencies
Mr. McKnight plans to continue coordinating with management on potential financing opportunities, in which he may participate as an investor. The Company notes that there can be no guarantee these financing opportunities will be successfully negotiated. The filing includes standard forward-looking statement disclaimers regarding risks and uncertainties that could cause actual results to differ from expectations.
Key Facts for Investor Verification
- Verify the timeline for appointing a third member to the Audit Committee to ensure compliance with the 180-day Nasdaq cure period.
- Confirm whether Mr. McKnight's potential financing opportunities materialize and the actual amount raised, if any.
- Review the full text of Amendment No. 1 to the Letter Agreement with Mr. Nagar (Exhibit 10.1) to understand the specific terms of the board seat replacement mechanism.
- Monitor future filings for Mr. McKnight's specific committee assignments, which were not determined at the time of this filing.